Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

- PMLiVE

Alkermes boosts CNS presence with $950m Rodin acquisition

Follows company making job cuts in September as part of cost-saving efforts

- PMLiVE

Biogen under fire over $88,000 Vumerity annual price

Pricing pressure levelled at Tecfidera follow-up MS drug

- PMLiVE

Rethinking trials: the pros and cons of protocol amendments

Protocol amendments occur often and can be beneficial, but the steps involved can be complex

- PMLiVE

Don’t we all need to be able to change something?

Surely no one plans for a ‘life of easy’, where nothing happens. Easy sounds good, but surely life’s challenges present the opportunity to shine (even fail, with the chance to...

- PMLiVE

Antibiotic resistance: The silent pandemic

Porterhouse is proud to support World Antibiotic Awareness Week. Our article aims to improve awareness of one of the biggest threats to global health today: antibiotic resistance.

Porterhouse Medical Group

Roche Basel Switzerland

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

Portfolio includes phase 2 candidate with FDA breakthrough status

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

- PMLiVE

Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

Sanofi Genzyme’s Lemtrada and Pfizer's Xeljanz receive label restrictions

- PMLiVE

The NHS is facing shortages of lifesaving treatments, says internal document

Identifies 17 new shortages including drugs for cancer treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links